Cite
HARVARD Citation
Motzer, R. et al. (n.d.). LBA54ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). Annals of oncology. p. . [Online].